Sanjivani Paranteral
193.40
-10.55(-5.17%)
Market Cap₹237.54 Cr
PE Ratio33.60
IndustryHealthcare
Company Performance:
1D-5.17%
1M-13.27%
6M-7.64%
1Y-41.03%
5Y+1,781.32%
View Company Insightsright
More news about Sanjivani Paranteral
18Aug 25
Sanjivani Parenteral Reports 8.9% Revenue Growth in Q1, Pune Facility Set for Commercial Production
Sanjivani Parenteral Limited, a WHO-GMP certified pharmaceutical company, reported Q1 revenue growth of 8.9% YoY to INR 17.90 crores. EBITDA increased by 10.8% to INR 2.70 crores, with margins improving to 15.00%. The company maintains a 73.70%-26.30% export-domestic revenue mix, exporting to over 25 countries. Their new Pune facility is expected to begin commercial production by early September. The company added 8 new products in Q1 and Q2 combined and is focusing on expanding in LATAM and French-speaking African markets. Despite logistical challenges, management remains optimistic, providing a full-year revenue guidance of INR 75-80 crores.
12Aug 25
Sanjivani Paranteral Reports 8.9% Revenue Growth in Q1 FY26, Driven by Strong Injectables Performance
Sanjivani Paranteral Limited reported an 8.9% year-over-year revenue growth to ₹178.90 crore for Q1 FY26. EBITDA increased by 10.8% to ₹26.80 crore, while PAT grew marginally by 1.0% to ₹17.30 crore. The injectables segment showed robust growth of 47.1%, but the oral segment declined by 11.1% due to shipment challenges. Exports constituted 73.7% of total revenue, with core markets in CIS, Middle East & Africa, and Latin America contributing significantly. The company remains focused on R&D and expanding its product portfolio to drive future growth.
Sanjivani Paranteral
193.40
-10.55
(-5.17%)
1 Year Returns:-41.03%
Industry Peers
Sun Pharmaceutical
1,700.70
(-1.62%)
Divis Laboratories
6,355.50
(-1.26%)
Torrent Pharmaceuticals
4,003.70
(+1.61%)
Cipla
1,434.50
(-0.95%)
Lupin
2,195.90
(+0.78%)
Dr Reddys Laboratories
1,186.50
(-0.40%)
Mankind Pharma
2,244.40
(+1.38%)
Zydus Life Science
883.75
(-1.88%)
Alkem Laboratories
5,830.50
(-0.56%)
Aurobindo Pharma
1,180.10
(+1.06%)